← Back to Search

Keratoprosthesis

CorNeat KPro for Corneal Blindness

N/A
Recruiting
Research Sponsored by CorNeat Vision Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female aged ≥ 21 and ≤ 80 years on the day of screening
Legally blind (BCVA of 6/120 or worse in the better eye) in one or two eyes. In case of unilateral blindness - BCVA of Counting Fingers (CF) from 1 meter or worse in the operated eye
Must not have
Hemoglobin A1C (HbA1c) higher than 8% at screening indicating unbalanced diabetes and/or target organ damage associated with diabetes
Patients requiring anticoagulation treatment, which cannot be interrupted for the surgical procedure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months post-op
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new eye device to help restore vision in those with corneal blindness.

Who is the study for?
Adults aged 21-80 with legal blindness due to corneal diseases, who've had unsuccessful corneal transplants or aren't candidates for them. Must be able to follow study procedures and have adequate tear film and lid function. Women of childbearing age must use contraception.
What is being tested?
The trial is testing the CorNeat KPro, a device designed as a treatment for corneal blindness. This single-arm study involves multiple centers and doesn't compare against other treatments but measures safety and performance in eligible participants.
What are the potential side effects?
While specific side effects are not listed, potential risks may include those typical of eye surgeries such as infection, inflammation, increased intraocular pressure, or rejection of the device leading to further vision loss.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 21 and 80 years old.
Select...
I am legally blind in one or both eyes.
Select...
I need a special cornea surgery because regular cornea transplants have failed or are not suitable for me.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My diabetes is not well-controlled, with an HbA1c over 8%.
Select...
I need continuous anticoagulation treatment that can't be stopped for surgery.
Select...
I currently have an infection and am taking antibiotics.
Select...
My doctor expects I have less than two years to live due to my illness.
Select...
My corneal thickness is either below 400 or above 1200 microns.
Select...
I have been diagnosed with ocular ischemic syndrome.
Select...
I have a corneal disorder, but it's not in the central part of my eye.
Select...
I had no surgery issues that would stop me from getting the study device.
Select...
I have a working eye pressure control device or surgery.
Select...
I am currently experiencing a detached retina.
Select...
My target eye has connective tissue disease or severe scarring.
Select...
I have advanced or uncontrolled glaucoma.
Select...
I have had severe eye inflammation diseases.
Select...
I have had cancer in or around my eye.
Select...
I have active eye inflammation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months post-op
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months post-op for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety Assessment
Secondary study objectives
Change in Best Corrected Distance Visual Acuity (BCDVA) from baseline
Retention rate

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CorNeat KProExperimental Treatment1 Intervention
Intraocular implantation of the CorNeat KPro

Find a Location

Who is running the clinical trial?

CorNeat Vision Ltd.Lead Sponsor
3 Previous Clinical Trials
50 Total Patients Enrolled
1 Trials studying Corneal Diseases
10 Patients Enrolled for Corneal Diseases

Media Library

CorNeat KPro (Keratoprosthesis) Clinical Trial Eligibility Overview. Trial Name: NCT05694247 — N/A
Corneal Diseases Research Study Groups: CorNeat KPro
Corneal Diseases Clinical Trial 2023: CorNeat KPro Highlights & Side Effects. Trial Name: NCT05694247 — N/A
CorNeat KPro (Keratoprosthesis) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05694247 — N/A
~10 spots leftby Mar 2025